Strong Buy
Average AnalystN/A
Top AnalystSlightly Bullish
Stock Target AdvisorN/A
Average UserINR 509.45
+30.75 (+6.42)%
INR 88.51B
0.70M
INR 600.00(+17.77%)
Based on the Blue Jet Healthcare Limited stock forecast from 1 analysts, the average analyst target price for Blue Jet Healthcare Limited is INR 600.00 over the next 12 months. Blue Jet Healthcare Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Blue Jet Healthcare Limited is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Blue Jet Healthcare Limited’s stock price was INR 509.45. Blue Jet Healthcare Limited’s stock price has changed by +4.21% over the past week, +8.34% over the past month and 0% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.